Related Experiment Videos
[Intermittent hormone therapy for prostate cancer]
1Service d'urologie, hôpital Cochin, Paris, France. michael.peyromaure@cch.ap-hop-paris.fr
Annales D'Urologie
|November 24, 2005
Summary
Intermittent hormone therapy for prostate cancer offers potential benefits like delayed hormone independence and fewer side effects. While feasible and comparable to continuous therapy, long-term superiority requires further study.
Area of Science:
- Oncology
- Urology
Context:
- Prostate cancer treatment often involves continuous hormone therapy.
- Intermittent hormone therapy (IHT) is an alternative treatment schedule.
Purpose:
- To evaluate the feasibility, oncologic outcomes, and side effect profile of intermittent hormone therapy in prostate cancer patients.
- To compare IHT with continuous hormone therapy regarding treatment efficacy and patient quality of life.
Summary:
- Intermittent hormone therapy involves cycles of treatment and off-treatment periods based on prostate-specific antigen (PSA) levels.
- Phase II trials suggest IHT is feasible, with patients experiencing 40-50% of treatment time off therapy.
- Oncologic results appear equivalent to continuous therapy, with reduced side effects and improved quality of life during off-treatment phases.
Impact:
- IHT may offer a way to mitigate side effects and improve quality of life in prostate cancer management.
- Further comparative trials are necessary to establish the long-term superiority of IHT over continuous hormone therapy.